annual cash & cash equivalents:
$1.10B+$674.58M(+157.45%)Summary
- As of today (June 22, 2025), SRPT annual cash & cash equivalents is $1.10 billion, with the most recent change of +$674.58 million (+157.45%) on December 31, 2024.
- During the last 3 years, SRPT annual cash & cash equivalents has fallen by -$1.01 billion (-47.87%).
- SRPT annual cash & cash equivalents is now -47.87% below its all-time high of $2.12 billion, reached on December 31, 2021.
Performance
SRPT Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$240.87M-$862.14M(-78.16%)Summary
- As of today (June 22, 2025), SRPT quarterly cash & cash equivalents is $240.87 million, with the most recent change of -$862.14 million (-78.16%) on March 1, 2025.
- Over the past year, SRPT quarterly cash & cash equivalents has dropped by -$186.42 million (-43.63%).
- SRPT quarterly cash & cash equivalents is now -88.62% below its all-time high of $2.12 billion, reached on December 31, 2021.
Performance
SRPT quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SRPT Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +157.4% | -43.6% |
| 3 y3 years | -47.9% | -80.5% |
| 5 y5 years | +32.1% | -86.3% |
SRPT Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -47.9% | +157.4% | -80.5% | +21.7% |
| 5 y | 5-year | -47.9% | +157.4% | -88.6% | +21.7% |
| alltime | all time | -47.9% | >+9999.0% | -88.6% | >+9999.0% |
SRPT Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $240.87M(-78.2%) |
| Dec 2024 | $1.10B(+157.5%) | $1.10B(+457.5%) |
| Sep 2024 | - | $197.85M(-48.4%) |
| Jun 2024 | - | $383.62M(-10.2%) |
| Mar 2024 | - | $427.29M(-0.3%) |
| Dec 2023 | $428.43M(-55.7%) | $428.43M(-20.9%) |
| Sep 2023 | - | $541.93M(-36.4%) |
| Jun 2023 | - | $851.93M(-2.3%) |
| Mar 2023 | - | $871.67M(-9.8%) |
| Dec 2022 | $966.78M(-54.3%) | $966.78M(-6.9%) |
| Sep 2022 | - | $1.04B(+19.6%) |
| Jun 2022 | - | $868.57M(-29.6%) |
| Mar 2022 | - | $1.23B(-41.7%) |
| Dec 2021 | $2.12B(+40.8%) | $2.12B(+32.3%) |
| Sep 2021 | - | $1.60B(-5.8%) |
| Jun 2021 | - | $1.70B(+14.5%) |
| Mar 2021 | - | $1.48B(-1.4%) |
| Dec 2020 | $1.50B(+79.9%) | $1.50B(+1.9%) |
| Sep 2020 | - | $1.47B(-10.1%) |
| Jun 2020 | - | $1.64B(-7.0%) |
| Mar 2020 | - | $1.76B(+111.3%) |
| Dec 2019 | $835.08M(+125.2%) | $835.08M(+15.2%) |
| Sep 2019 | - | $724.83M(-10.4%) |
| Jun 2019 | - | $808.59M(+10.4%) |
| Mar 2019 | - | $732.19M(+97.4%) |
| Dec 2018 | $370.83M(-38.2%) | $370.83M(+76.8%) |
| Sep 2018 | - | $209.70M(-48.9%) |
| Jun 2018 | - | $410.38M(-26.4%) |
| Mar 2018 | - | $557.23M(-7.1%) |
| Dec 2017 | $599.69M(+389.9%) | $599.69M(-2.9%) |
| Sep 2017 | - | $617.63M(+266.9%) |
| Jun 2017 | - | $168.35M(-38.7%) |
| Mar 2017 | - | $274.72M(+124.4%) |
| Dec 2016 | $122.42M(+52.4%) | $122.42M(-69.0%) |
| Sep 2016 | - | $395.14M(+253.4%) |
| Jun 2016 | - | $111.82M(+194.3%) |
| Mar 2016 | - | $38.00M(-52.7%) |
| Dec 2015 | $80.30M(+9.2%) | $80.30M(+43.9%) |
| Sep 2015 | - | $55.82M(-19.7%) |
| Jun 2015 | - | $69.54M(-6.6%) |
| Mar 2015 | - | $74.44M(+1.2%) |
| Dec 2014 | $73.55M(-71.4%) | $73.55M(+40.6%) |
| Sep 2014 | - | $52.30M(-49.1%) |
| Jun 2014 | - | $102.75M(+109.3%) |
| Mar 2014 | - | $49.10M(-80.9%) |
| Dec 2013 | $256.96M(+36.9%) | $256.96M(-6.1%) |
| Sep 2013 | - | $273.64M(+75.2%) |
| Jun 2013 | - | $156.19M(-7.0%) |
| Mar 2013 | - | $167.92M(-10.5%) |
| Dec 2012 | $187.66M(+370.3%) | $187.66M(+394.0%) |
| Sep 2012 | - | $37.99M(+55.1%) |
| Jun 2012 | - | $24.49M(-19.9%) |
| Mar 2012 | - | $30.57M(-23.4%) |
| Dec 2011 | $39.90M(+18.8%) | $39.90M(-13.9%) |
| Sep 2011 | - | $46.36M(-14.5%) |
| Jun 2011 | - | $54.19M(+132.7%) |
| Mar 2011 | - | $23.28M(-30.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2010 | $33.59M(-30.4%) | $33.59M(-6.6%) |
| Sep 2010 | - | $35.97M(-2.1%) |
| Jun 2010 | - | $36.74M(-11.3%) |
| Mar 2010 | - | $41.44M(-14.2%) |
| Dec 2009 | $48.27M(+331.3%) | $48.27M(-4.0%) |
| Sep 2009 | - | $50.27M(+150.9%) |
| Jun 2009 | - | $20.04M(-19.0%) |
| Mar 2009 | - | $24.72M(+120.9%) |
| Dec 2008 | $11.19M(-54.9%) | $11.19M(-20.5%) |
| Sep 2008 | - | $14.08M(-23.9%) |
| Jun 2008 | - | $18.51M(-7.3%) |
| Mar 2008 | - | $19.96M(-19.5%) |
| Dec 2007 | $24.80M(+23.0%) | $24.80M(+542.3%) |
| Sep 2007 | - | $3.86M(-58.3%) |
| Jun 2007 | - | $9.26M(-38.1%) |
| Mar 2007 | - | $14.96M(-25.8%) |
| Dec 2006 | $20.16M(-41.7%) | $20.16M(-21.2%) |
| Sep 2006 | - | $25.58M(-19.5%) |
| Jun 2006 | - | $31.76M(-13.8%) |
| Mar 2006 | - | $36.87M(+6.6%) |
| Dec 2005 | $34.60M(+107.7%) | $34.60M(+25.6%) |
| Sep 2005 | - | $27.56M(+0.8%) |
| Jun 2005 | - | $27.35M(-20.4%) |
| Mar 2005 | - | $34.36M(+106.3%) |
| Dec 2004 | $16.65M(+33.0%) | $16.65M(+34.9%) |
| Sep 2004 | - | $12.34M(+11.7%) |
| Jun 2004 | - | $11.04M(+27.1%) |
| Mar 2004 | - | $8.69M(-30.6%) |
| Dec 2003 | $12.52M(+20.6%) | $12.52M(+91.8%) |
| Sep 2003 | - | $6.53M(-28.1%) |
| Jun 2003 | - | $9.08M(+26.6%) |
| Mar 2003 | - | $7.17M(-30.9%) |
| Dec 2002 | $10.38M(-6.2%) | $10.38M(-17.5%) |
| Sep 2002 | - | $12.59M(-6.4%) |
| Jun 2002 | - | $13.45M(-55.0%) |
| Mar 2002 | - | $29.89M(+170.0%) |
| Dec 2001 | $11.07M(-57.3%) | $11.07M(-55.0%) |
| Sep 2001 | - | $24.61M(-12.5%) |
| Jun 2001 | - | $28.13M(+27.9%) |
| Mar 2001 | - | $22.00M(-15.0%) |
| Dec 2000 | $25.90M(+197.7%) | $25.90M(-12.4%) |
| Sep 2000 | - | $29.55M(+325.3%) |
| Jun 2000 | - | $6.95M(-27.5%) |
| Mar 2000 | - | $9.58M(+10.1%) |
| Dec 1999 | $8.70M(+2.4%) | $8.70M(+262.5%) |
| Sep 1999 | - | $2.40M(-45.5%) |
| Jun 1999 | - | $4.40M(-34.3%) |
| Mar 1999 | - | $6.70M(-21.2%) |
| Dec 1998 | $8.50M(-51.7%) | $8.50M(-22.0%) |
| Sep 1998 | - | $10.90M(-17.4%) |
| Jun 1998 | - | $13.20M(-16.5%) |
| Mar 1998 | - | $15.80M(-10.2%) |
| Dec 1997 | $17.60M(+486.7%) | $17.60M(-4.9%) |
| Sep 1997 | - | $18.50M(+5.1%) |
| Jun 1997 | - | $17.60M(+665.2%) |
| Mar 1997 | - | $2.30M |
| Dec 1996 | $3.00M | - |
FAQ
- What is Sarepta Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual cash & cash equivalents year-on-year change?
- What is Sarepta Therapeutics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly cash & cash equivalents year-on-year change?
What is Sarepta Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SRPT is $1.10B
What is the all time high annual cash & cash equivalents for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual cash & cash equivalents is $2.12B
What is Sarepta Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SRPT annual cash & cash equivalents has changed by +$674.58M (+157.45%)
What is Sarepta Therapeutics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of SRPT is $240.87M
What is the all time high quarterly cash & cash equivalents for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly cash & cash equivalents is $2.12B
What is Sarepta Therapeutics quarterly cash & cash equivalents year-on-year change?
Over the past year, SRPT quarterly cash & cash equivalents has changed by -$186.42M (-43.63%)